• ScreenPro (SCRN) has completed its acquisition of Concierge Medical Consultants from Datametrex AI (DM)
  • Concierge Medical is an arm’s length private medical concierge services provider
  • The company paid a purchase price of C$1,800,000 in common shares
  • It views the acquisition as a strategic component of its post-pandemic business plan
  • ScreenPro Security is a medical technology company that offers proprietary testing methods and medical alerting software
  • ScreenPro (SCRN) is unchanged trading at $0.02 per share

ScreenPro (SCRN) has completed its acquisition of Concierge Medical Consultants from Datametrex AI (DM).

Concierge Medical is an arm’s length private medical concierge services provider incorporated under the laws of British Columbia. It’s comprised of a small group of board-certified practicing emergency physicians and was founded by Dr. Jibran Sharif, MD, CCFP EM, RDMS.

The company issued 36,000,000 common shares priced at C$0.05 per share for an aggregate purchase price of $1,800,000.

Lena Kozovski, CEO of ScreenPro, stated,

“We are pleased to complete the acquisition of Concierge Medical. Dr. Sharif and I have worked together for the last year on the pandemic and COVID-19 testings, and I look forward to moving Concierge Medical to the next level. Consumers view concierge services as a viable model for future medical care needs and the completion of this acquisition is a pivotal part of our post-pandemic business plan.”

Concierge Medical has become ScreenPro’s wholly-owned operating subsidiary. Sharif and Kozovski now make up Concierge Medical’s Board of Directors, with Sharif remaining as President and assuming the role of ScreenPro’s Chief Medical Officer.

ScreenPro Security is a medical technology company that offers proprietary testing methods and medical alerting software.

ScreenPro (SCRN) is unchanged trading at $0.02 per share as of 9:30 am ET.

More From The Market Online

Calian scores $23 million Canadian Armed Forces contract

Calian Group Ltd. (TSX:CGY) has been awarded a $17 million contract by the Canadian Armed Forces’ Canadian Forces Health Services Group.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

This life sciences company is gearing up to treat long COVID  

Revive Therapeutics (CSE:RVV), a Toronto-based company, has immense potential to capitalize on treating long COVID symptoms.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.